Since some ApoE4 carriers do not develop AD even at a great age, other factors, such as amylin, may interact with ApoE4 to influence AD development. High plasma levels of amylin were associated with obesity and type 2 diabetes, as well as with other biomarkers of metabolic syndrome and cerebrovascular disease including low HDL levels, high creatinine levels, and non-linear increased levels of cholesterol and LDL. These data suggest a relationship between amylin Nutlin-3 resistance, obesity, and type 2 diabetes, which is consistent with findings in other studies . Amylin was independently associated with Ab even after adjusting for these biomarkers of metabolic syndrome. Since amylin is cleared by the kidney, the relationship between plasma amylin and Ab, especially Ab1-40, was influenced by adding creatinine to the models. Amylin’s major role in the brain is to reduce food intake thereby controlling body weight and regulating glucose metabolism. Administering exogenous amylin, either peripherally or intracerebroventricularly, results in reduced appetite and food intake. Pramlintide, an amylin analog differing by three amino acids, is an effective and well-tolerated drug in clinical use for the treatment of diabetes . Given the effectiveness of the amylin class of peptides in reducing amyloid pathology in the brain in the preclinical study and the relationship between amylin and Ab in the context of ApoE allele seen in this human study, pramlintide may have potential as a treatment in AD. A clinical trial of pramlintide in AD, an off-label use, may be warranted. Limitations of our study are its cross-sectional design and lack of brain imaging. Longitudinal studies are needed to confirm the causal relationship between high levels of plasma amylin and decreased Abdeposition in the brain. There were no diagnoses of AD and mild cognitive impairment for this population based study. Future studies are necessary to examine the concentrations of amylin and its relationship to Ab in specific diagnostic groups. Gastric cancer is the second most frequent cause of death from cancer in the world. Thus far, few tumor suppressor genes and tumor-related genes have been reported in GC. Although extensive studies have been performed to identify genetic pathways and mechanisms involved in cancer development, few improvements on the early diagnosis of cancer have been made. MicroRNAs are endogenous small noncoding RNAs that have been identified as posttranscriptional regulators of gene expression. Previous studies have indicated that miRNAs exert their functions through imperfect base-pairing with the 39untranslated region of target mRNAs and miRNAs have been extensively studied in the context of cell cycle regulation, differentiation, development and apoptosis. Accumulated evidence indicates that miRNAs are deregulated in various diseases, especially in cancer. For example, miR-216b is markedly down-regulated in nasopharyngeal carcinoma; miR340 is deregulated in breast cancer and can inhibit breast cancer cell migration and invasion.